Poland

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)

This Phase 3 clinical trial, known as PRISM-MEL-301, is investigating whether a new immunotherapy treatment called brenetafusp (IMC-F106C), given in combination with nivolumab, works better than standard nivolumab-based treatment for people with advanced melanoma that cannot be removed surgically or has spread to other parts of the body. The study is specifically for patients who […]

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301) Read More »

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466

This early-phase clinical trial is testing a new treatment called brenetafusp (IMC-F106C) for adults with advanced cancers that test positive for a specific protein called PRAME. Brenetafusp is a type of immunotherapy known as an ImmTAC®, which is designed to help the immune system find and destroy cancer cells. To take part in the trial, patients must also

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466 Read More »

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma – NCT05987332

This Phase 1/2 multi-centre, open-label basket study aims to assess the safety and effectiveness of IDE196 in treating solid tumours with specific genetic changes, such as GNAQ or GNA11 mutations or PRKC fusions. The study includes patients with metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other types of solid tumours.

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma – NCT05987332 Read More »